Consensus statement on depression, anxiety, and oncology.
Consensus statement on depression, anxiety, and oncology.
复制标题
DOI：
--
复制
发表时间：
2001-07
期刊：
影响因子：
--
通讯作者：
J. Ballenger;Jonathan R. T. Davidson;Y. Lecrubier;D. Nutt;Richard D Jones;R. Berard
中科院分区：
文献类型：
--
作者：
J. Ballenger;Jonathan R. T. Davidson;Y. Lecrubier;D. Nutt;Richard D Jones;R. Berard
C治疗与衰弱化疗方案，免疫反应调节剂，慢性疼痛与他们的身体疾病。除了诊断出危及生命的疾病对正常情绪的影响外，估计有20%至25%的癌症患者符合重度抑郁或焦虑的诊断标准，这些可治疗的精神疾病对他们的生活质量有严重的不利影响。[1]在我们关于抑郁症和焦虑症在全科医学中的共识会议上，抑郁症和焦虑症国际共识小组从肿瘤学家和精神病学家的角度回顾了抑郁症、焦虑症和肿瘤学。本文阐述了我们对肿瘤患者抑郁和焦虑的检测和诊断的看法，探讨了管理问题，并确定了进一步的研究领域。
Ctreatment with debilitating chemotherapy regimens, immune response modifiers, and chronic pain associated with their physical illness. Quite apart from the normal emotional impact of the diagnosis of a life-threatening illness, an estimated 20% to 25% of cancer patients meet diagnostic criteria for major depression or anxiety, treatable psychiatric conditions that have serious detrimental effects on their quality of life. 1 At our consensus meeting on depressive and anxiety disorders in general medicine, the International Consensus Group on Depression and Anxiety reviewed depression, anxiety, and oncology from the perspectives of both the oncologist and the psychiatrist. This article sets forth our views on the detection and diagnosis of depression and anxiety in the oncology patient, examines management issues, and identifies further areas for research.